Henlius, Organon trial drug meets goal of an absence of breast cancer
Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.
Drugs
Health
Pharma
Drugs
Health
Pharma
Cambridge Univ. researchers develop ‘jelly batteries’ for devices, implants
Cambridge University researchers, taking inspiration from electric eels, have developed stretchable ‘jelly batteries’ that could be used to deliver drugs or treat conditions.
Drugs
Health
Pharma
Regeneron-Sanofi’s drug for lung disease gets US approval
Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.
Drugs
Health
Pharma
FDA approves Cobenfy, a new treatment for schizophrenia
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.
Drugs
Health
Pharma
World leaders call for action to combat antimicrobial resistance threat
HQ Team September 27, 2024: World leaders convened at the United Nations General Assembly (UNGA) on September 26, to address the escalating threat.
Drugs
Health
Pharma
Indian drug body alerts public to 52 spurious medicines in market
HQ Team September 27, 2024: The Central Drugs Standard Control Organisation (CDSCO) of India recently issued a notification regarding identifying 52 spurious drugs.
Drugs
Health
Medical
New research highlights alcohol use and cancer risk link
HQ Team September 26, 2024: A recent report from the American Association for Cancer Research (AACR) reveals that though cancer-related fatalities have decreased.
Drugs
Health
Pharma
Evotec SE in pact with Novo Nordisk to develop cell therapy products
Evotec SE has signed a technology pact with Novo Nordisk to produce cell therapy products for clinical development and commercial use, according to.
Drugs
Health
Pharma
Pfizer pulls out sickle cell therapy from global markets, cites death, snags
Pfizer Inc.’s sickle cell therapy involving Oxbryta has been voluntarily withdrawn from global markets due to painful complications and death, according to a.
Drugs
Health
Pharma
Merck’s trial drug combination for colorectal cancer fails main goal
Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.